Tag: FDA

CHC_Legislative1

User Fee Legislation Markup Suggests Added FDA Regulatory Authorities

CHC-offLabel2

Clinical Trials Not Sufficiently Diverse – and Diversity Data Often Not Reported

CHC_general2

CMS Sticks to Plan: No Aduhelm Coverage Unless in Clinical Trial

CHC_washingtonfocus2

Biden’s 2023 Budget: Big Increases for FDA, CDC, Pandemic Preparedness

Nancy Myers.NEWS

Myers: Data Will Drive Califf’s Decisions at FDA

Rawson.News

Fallout from Aduhelm Decision Could Undermine FDA Accelerated Approval Process

Rawson.News

Rawson: Biden Health Policy Priorities Include COVID, ARPA-H, Moonshot

CHC_Legislative1

Delays Add Pressure to User Fee Legislative Process

Robert-Califf-FDA.news

Califf Confirmation in Jeopardy?